M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...

Capricor's biologics license application for deramiocel (CAP-1002) is draws largely on the Phase 2 HOPE-2 trial and its ...

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) saw strong trading volume on Friday . 413,080 shares were traded during trading, a decline of 47% from the previous session’s volume ...

Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy: San Diego Saturday, January 4, 2025, 15:00 Hrs [IST] Capricor Therapeu ...

Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target ...

It is in with the new and out with the old today as the first session of the 119 th U.S. Congress is called to order. Although Republicans will control both the House and Senate for the next two years ...

Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...

Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

This milestone has triggered a $10 million milestone payment to Capricor from Nippon Shinyaku, the company's distribution ...

Shares of Capricor Therapeutics ($CAPR) were up 8.41% up on Thursday after the rare diseases-focused biotech said it ...

HC Wainwright reissued their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note ...